proxyvotesnow.com

Home › Companies › Mirum Pharmaceuticals, Inc. › 2025-2026

Mirum Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 350Asset managers
  • 2,101Fund votes
  • 2026-06-15Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Mirum Pharmaceuticals, Inc.

These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Mirum Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-15
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Lon Cardon, Ph.D., FMedSci 39,587,327---- 6,827,2143,614,839 Majority: yes
Elect Director: William Fairey 40,266,848---- 6,147,6933,614,839 Majority: yes
Elect Director: Timothy Walbert 32,329,718---- 14,084,8233,614,839 Majority: yes
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in 49,993,5145,67430,192 ---- Majority: yes
Proposal 3. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting. 44,534,5751,866,71913,247 --3,614,839 Majority: yes

Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the Mirum Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 350 asset managers that disclosed a Mirum Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 44,534,575AGAINST: 1,866,719

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual”): 44,534,575 for, 1,866,719 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,926,165 outstanding shares: 73% for, 3% against (76% of the company cast a for/against vote).

The 346 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 96%
FOR: 95.6%AGAINST: 4.4%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson11,472,2570 00For
Fidelity5,823,1260 00For
Vanguard4,400,3433 00For
T. Rowe Price2,440,5060 00For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock2,209,1540 00For
State Street1,643,8580 00For
Capital Group01,448,830 00Against
MUTUAL FUND SERIES TRUST1,316,7390 00For
BVF INC/IL1,259,7270 00For
GEODE CAPITAL MANAGEMENT, LLC1,210,7770 00For
Novo Holdings A/S1,125,0000 00For
Charles Schwab854,9580 00For
Federated Hermes842,7530 00For
FRANKLIN ADVISERS INC790,6980 00For
Loomis Sayles706,2610 00For
Rock Springs Capital Management LP701,6660 00For
Wellington692,6130 00For
Clearbridge Investments, LLC650,9610 00For
Paradigm Biocapital Advisors LP560,3050 00For
Polar Capital Holdings Plc535,5920 00For
RA CAPITAL MANAGEMENT, L.P.509,6860 00For
LORD, ABBETT & CO. LLC484,8450 00For
Invesco463,5230 00For
Nuveen444,4840 00For

Showing the 25 largest of 346 asset managers. See all 346 in the interactive database.

2. To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSci

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%
FOR: 39,587,327WITHHELD: 6,827,214

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lon Cardon, Ph.D., FMedSci”): 39,587,327 for, 6,827,214 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,926,165 outstanding shares: 65% for, 11% withheld (76% of the company cast a for/withheld vote).

The 107 asset managers below cast 100% of the shares they voted on this item FOR (18,796,478 for, 0 against).

FOR 87%13%
FOR: 18,796,478 (87.4%)ABSTAIN: 2,715,531 (12.6%)
Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,996,1950 15,6300For
Fidelity3,343,6630 4000For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,430,8780 00For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,018,0420 1,1700For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 377,5520Abstain
Legg Mason373,6150 2,7760For
Federated Hermes348,0280 00For
Loomis Sayles00 259,0220Abstain
Waddell & Reed00 234,8170Abstain
Bridge Builder Trust130,5390 80,9720For
Invesco211,4010 00For
Erste Asset Management GmbH00 210,0000Abstain
MFS00 198,8360Abstain
BNY Mellon156,0350 1,4490For
RBB FUND, INC.00 156,1540Abstain
Manager Directed Portfolios151,8710 00For
First Trust00 127,0790Abstain
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

3. To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy Walbert

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD 30%
FOR: 32,329,718WITHHELD: 14,084,823

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Timothy Walbert”): 32,329,718 for, 14,084,823 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,926,165 outstanding shares: 53.1% for, 23% withheld (76% of the company cast a for/withheld vote).

The 107 asset managers below cast 100% of the shares they voted on this item FOR (14,838,879 for, 0 against).

FOR 69%ABSTAIN 31%
FOR: 14,838,879 (69.0%)ABSTAIN: 6,673,129 (31.0%)
Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meet” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,994,0610 17,7640For
Fidelity3,326,4120 17,6510For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock92,1250 1,338,7530Abstain
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street2,0120 1,017,2000Abstain
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab00 427,3750Abstain
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 377,5520Abstain
Legg Mason373,6150 2,7760For
Federated Hermes348,0280 00For
Loomis Sayles00 259,0220Abstain
Waddell & Reed00 234,8170Abstain
Bridge Builder Trust122,5000 89,0110For
Invesco00 211,4010Abstain
Erste Asset Management GmbH00 210,0000Abstain
MFS00 198,8360Abstain
BNY Mellon00 157,4840Abstain
RBB FUND, INC.00 156,1540Abstain
Manager Directed Portfolios151,8710 00For
First Trust00 127,0790Abstain
Columbia Threadneedle00 121,3230Abstain

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

4. To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William Fairey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 40,266,848WITHHELD: 6,147,693

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Fairey”): 40,266,848 for, 6,147,693 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,926,165 outstanding shares: 66% for, 10% withheld (76% of the company cast a for/withheld vote).

The 107 asset managers below cast 100% of the shares they voted on this item FOR (19,281,381 for, 0 against).

FOR 90%10%
FOR: 19,281,381 (89.6%)ABSTAIN: 2,230,628 (10.4%)
Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,996,1960 15,6290For
Fidelity3,336,1290 7,9340For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,338,7530 92,1250For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,018,0420 1,1700For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 377,5520Abstain
Legg Mason373,6150 2,7760For
Federated Hermes348,0280 00For
Loomis Sayles259,0220 00For
Waddell & Reed00 234,8170Abstain
Bridge Builder Trust211,5110 00For
Invesco211,4010 00For
Erste Asset Management GmbH00 210,0000Abstain
MFS198,8360 00For
BNY Mellon156,0350 1,4490For
RBB FUND, INC.00 156,1540Abstain
Manager Directed Portfolios151,8710 00For
First Trust00 127,0790Abstain
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

5. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 49,993,514AGAINST: 5,674

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 49,993,514 for, 5,674 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,926,165 outstanding shares: 82% for, 0.1% against (82% of the company cast a for/against vote).

The 107 asset managers below cast 100% of the shares they voted on this item FOR (21,507,912 for, 0 against).

FOR 99.9%
FOR: 21,507,912 (100.0%)ABSTAIN: 4,097 (0.0%)
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,011,8250 00For
Fidelity3,344,0630 00For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,430,8780 00For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,019,2120 00For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett377,5520 00For
Legg Mason376,3910 00For
Federated Hermes348,0280 00For
Loomis Sayles259,0220 00For
Waddell & Reed234,8170 00For
Bridge Builder Trust211,5110 00For
Invesco211,4010 00For
Erste Asset Management GmbH210,0000 00For
MFS198,8360 00For
BNY Mellon157,4840 00For
RBB FUND, INC.156,1540 00For
Manager Directed Portfolios151,8710 00For
First Trust127,0790 00For
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.

Largest Mirum Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Mirum Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,926,165 shares outstanding at the time of that meeting.

Top Mirum Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 18.83%
2Fidelity 9.56%
3Vanguard 7.22%
4T. Rowe Price 4.01%
5JANUS INVESTMENT FUND 3.84%
6BlackRock 3.63%
7State Street 2.70%
8Capital Group 2.38%
9MUTUAL FUND SERIES TRUST 2.16%
10BVF INC/IL 2.07%

Reported Mirum Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Mirum Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
JANUS HENDERSON GROUP Ltd. 9.70% 13G
Patrick Heron 6.74% DEF14A
James N. Topper 6.61% 13D
BlackRock 6.31% 13F
Frazier Life Sciences IX, L.P. 5.85% DEF14A
Vanguard Group 4.26% 13F
FMR (Fidelity) 3.23% 13F
State Street 3.19% 13F
Christopher Peetz 2.98% DEF14A
T. Rowe Price 2.82% 13F

Percentages above are of 60,926,165 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Mirum Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-15, in the 2025-2026 proxy season, 350 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,101 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).